Alzheimer’s disease was first recognised over 100 years ago and yet we still only have limited treatment options to delay, prevent or slow this disease.
Rachelle Doody, Roche’s Global Head of Neurodegeneration considers the advent of disease-modifying therapies for Alzheimer’s disease to be an encouraging sign of progress, and is confident that we are getting closer to our hope of effectively treating this debilitating condition. Rachelle joined the company in 2016 to ‘move on her mission’ after spending 25 years directing an Alzheimer’s disease centre in a medical school. Her background is in neurology and cognitive anthropology, but her training has been applied to understanding and treating Alzheimer’s disease. She is regarded as a global authority on clinical trials for Alzheimer’s disease and has published more than 200 original articles on the diagnosis, progression or treatment of Alzheimer's disease and related disorders. “My career has taught me that we have to think about neurodegenerative disorders from the molecule, to the cell, to society, in order to do something about them.”
Alzheimer’s disease is the most common type of dementia and currently affects around 50 million people worldwide. Alzheimer’s disease is acknowledged to be one of the most expensive diseases; with a cost to individuals and wider society. A worldwide quest is under way to find new treatments to tackle the challenge of Alzheimer's disease. Because new drugs take years to develop from concept to market—and because drugs that seem promising in early-stage studies may not work as hoped in large-scale trials—it is critical that research into Alzheimer's disease continues to accelerate.
Over the last 30 years, researchers have made remarkable progress in understanding healthy brain function and what goes wrong in Alzheimer's disease. As Rachelle points out, “Alzheimer’s is a challenging disease because it takes many years to develop. People have the changes in their brain of Alzheimer’s maybe 25 years before their first symptom.”
On research progress to date, Rachelle notes that: “In Alzheimer’s disease, there have been many well documented failures, but with each failure we have learnt so much more about this devastating disease. When I think about what we now know about how to design a clinical trial and how to choose a population of patients to test a given therapy, it’s clear that our understanding has deepened with each trial, even from those that weren’t successful. We now know that we need a different approach for prevention, a different approach for people in very early stages of disease, and yet a different approach for people with advanced disease.”
Our clinical development programmes are at the very heart of our work in Alzheimer’s disease. Developing and testing medicines to ensure they are safe for patients can take many years and cost many millions. Many of the new drugs in development aim to modify the disease process itself, by hindering one or more of the many wide-ranging brain changes that Alzheimer's causes. These changes offer potential "targets" for new drugs to potentially stop or slow the progress of the disease. Research to date has shown researchers that, for treatment to be successful, the disease needs to be detected and diagnosed as early as possible. The earlier treatment starts, the more impact it will have on how the disease progresses.
The complexity of the brain and the disease makes it difficult to know how well investigational medicines are working, and large-scale clinical trials are underway to test potential new treatments in as many different populations as possible.
Many Alzheimer’s disease clinical studies rely on the participation of volunteers. Some studies need people with Alzheimer’s to take part, but others need people with experience of caring for someone with dementia or healthy volunteers to act as a comparison. Studies investigating the prevention of Alzheimer’s disease may need people who are at risk of developing Alzheimer’s but are not experiencing symptoms to volunteer. These can be particularly challenging to recruit for but may help us to better understand how to prevent Alzheimer’s disease before symptoms develop.
Taking part in research gives people the opportunity to make a difference for the future. The contributions of participants can help to improve the understanding of dementia and how we can prevent it, develop new treatments, or improve the care available for people living with Alzheimer’s disease. The last word goes to Jill Smith, a Development Lead in Alzheimer’s disease at Roche: “It is only through the dedication, commitment and support of clinical trial volunteers that we can continue to advance towards potential treatments that can stop, slow or prevent Alzheimer’s disease.”
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.